Revising the Decision Analysis for Febrile Children at Risk for Occult Bacteremia in a Future Era of Widespread Pneumococcal Immunization

Abstract

Previous decision analyses (DA), which have attempted to determine a superior management option for febrile children at risk for occult bacteremia, have come to different conclusions based on their underlying assumptions. Most DAs have recommended a laboratory evaluation with antibiotic treatment or have concluded that all management options are roughly the same. The purpose of this revised DA is to determine which management strategy will be superior in an anticipated era of widespread pneumococcal immunization. Decision analysis methodology comparing the following 3 management options: Obs: observation, no tests, no antibiotics; CBC+: Complete blood count (CBC) first; if the white blood cell count (WBC) >15,000, then blood culture (BC) plus antibiotics (Abx); BC+Abx: BC+Abx for all patients. Assumptions include a current bacteremia rate of 2% to 4%, and 95% of this bacteremia is caused by S. pneumococcus (which has a 15% persistent bacteremia rate) with the remainder caused by virulent bacteria (which has a 100% persistent bacteremia rate), and other assumptions made by previous decision analysis publications. Pneumococcal vaccine efficacy rates of 0%, 50%, 75%, and 100% in preventing pneumococcal bacteremia were analyzed. Overall death and neurologic sequelae rates are lower with efficacious pneumococcal vaccine. The Obs strategy is superior for all efficacy rates (including 0%) if the negative consequences of treatment are high. If the negative consequences of treatment are low, the CBC+ strategy is superior at pneumococcal vaccine efficacy rates of 50% or greater. The absolute differences between the outcomes of the 3 strategies are small, making them similar. This decision analysis indicates that widespread efficacious pneumococcal vaccine will reduce the overall morbidity and mortality associated with pneumococcal bacteremia. This favors the Obs strategy, but the superior management strategy is still dependent on an assumption of the negative consequences of treatment. Since the outcome measures for each of the management strategies are similar numerically, the strategy chosen in clinical practice may consider other factors associated with the clinical encounter such as those described.

Get full access to this article

View all access options for this article.

References

1. Lieu TA , Schwartz JS , Jaffe DM , Fleisher GR . Strategies for diagnosis and treatment of children at risk for occult bacteremia: clinical effectiveness and cost-effectiveness. J Pediatr 1991;118:21-29.

2. Downs SM , McNutt RA , Margolis PA . Management of infants at risk for occult bacteremia: a decision analysis. J Pediatr 1991;118:11-20.

3. Baraff LJ , Bass JW , Fleisher GR , et al. Practice guideline for the management of infants and children 0 to 36 month of age with fever without a source. Pediatrics. 1993;92:1-12.

4. Baraff LJ , Bass JW , Fleisher GR , et al. Practice guideline for the management of children 0 to 35 months of age with fever without a source. Ann Emerg Med. 1993;22:1198-1210.

5. Kramer MS , Shapiro ED . Management of the young febrile child: a commentary on recent practice guidelines. Pediatrics. 1997;100:128-134.

6. Baraff LJ , Bass JW , Fleisher GR , et al. Commentary on practice guidelines. Pediatrics. 1997;100:134-136.

7. Schriger DL . Clinical guidelines in the setting of incomplete evidence. Pediatrics. 1997;100:136-136.

8. Bauchner H , Pelton SI . Management of the young febrile child: a continuing controversy. Pediatrics. 1997;100: 137-138.

9. Yamamoto LG , Worthley RG , Melish ME , Seto DSY . A revised decision analysis of strategies in the management of febrile children at risk for occult bacteremia. Am J Emerg Med. 1998;16:193-207.

10.

10. Black S , Shinefield H , Fireman B , et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr Infect Dis J 2000;19:187-195.

11.

11. A pneumococcal conjugate vaccine for infants and children. The Medical Letter 2000;42(issue 1074):25-27.

12.

12. Lee GM , Harper MB . Risk of bacteremia for febrile young children in the post-Haemophilus influenzae type B era. Arch Pediatr Adolesc Med. 1998;152:624-628.

13.

13. Kuppermann N . Occult bacteremia in young febrile children. Pediatr Clin North Am. 1999;46:1073-1109.

14.

14. Haddon RA , Barnett PL , Grimwood K , Hogg GG . Bacteraemia in febrile children presenting to a paediatric emergency department. Med J Aust. 1999;170:475-478.

15.

15. Ros SP , Herman BE , Beissel TJ . Occult bacteremia: is there a standard of care? Pediatr Emerg Care. 1994;10:264-267.

16.

16. Young PC . The management of febrile infants by primary-care pediatricians in Utah: comparison with published practice guidelines. Pedatriics. 1995;95:623-627.

17.

17. Finkelstein JA , Christiansen CL , Platt R . Fever in pediatric primary care: ocurrence, management, and oucomes. Pediatrics. 2000;105(1, Supp Pt 3):260-266.

18.

18. Bachur R , Harper MB . Reevaluation of outpatients with Streptococcus pnemoniae bacteremia. Pediatrics. 2000;105(3, Supp Pt 1):502-509.

19.

19. Yamamoto LG , Boychuk RB . Emegency department versus office seting and physician/patient kinship efects in the diagnostic and therapeutic strategies for febrile children at risk for occult bacteremia. Hawaii Med J 1997;56:209-214.